18 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Kunz, Medical Oncologist in New Haven, CT?
Dr. Pamela Kunz, MD is a Medical Oncologist, who primarily practices in New Haven, CT. She has been practicing for over 18 years and is board certified. Dr. Kunz completed her residency at Stanford University School of Medicine. Dr. Kunz is fluent in English and Spanish, and is currently seeing new patients. Dr. Kunz’s practice accepts Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Kunz’s office at (203) 785-6879.
What are Areas of Expertise for Dr. Kunz?
Dr. Pamela Kunz, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Kunz empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Gastrointestinal Cancer, Neuroendocrine Tumors, and comprehensive wellness support. Serving the New Haven, CT community, Dr. Kunz is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Kunz go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine
Is Dr. Kunz board certified as a Medical Oncologist?
Yes, Dr. Pamela Kunz, MD is board certified by the American Board of Internal Medicine since 2010, American Board of Radiology since 2010
What languages does Dr. Kunz speak?
Dr. Kunz and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Medical Oncologist like Dr. Kunz typically treat?
As a Medical Oncologist, Dr. Kunz diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Kunz. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Other non-cancerous neuroendocrine Tumor
- Neuroendocrine Tumor
- Secondary Neuroendocrine Tumor
- Benign Tumor
- Cancer
- Endocrine Disease
- Other benign neuroendocrine growths
- Various non-cancerous hormone-producing tumors
- Malignant NET
- Neuroendocrine Cancer
- NET Cancer
- Metastatic Neuroendocrine Tumor
- Spread NET
- Secondary NET
ICD-10 Codes:
- D3A8: Other benign neuroendocrine tumors
- C7A8: Other malignant neuroendocrine tumors
- C7B8: Other secondary neuroendocrine tumors
Also known as:
- Ileum Carcinoid Tumor
- Carcinoid Tumor
- Gastrointestinal Neuroendocrine Tumor Treatment (PDQ)
- Ileal Carcinoid
- Malignant Ileum Tumor
- Small Bowel NET
ICD-10 Codes:
- C7A012: Malignant carcinoid tumor of the ileum
Also known as:
- Pancreatic Cancer
- Pancreatic Neuroendocrine Tumor (Islet Cell Tumor) Treatment (PDQ®)
- Pancreatic Neuroendocrine Tumor
- Islet Cell Tumor
- Endocrine Pancreas Cancer
ICD-10 Codes:
- C254: Malignant neoplasm of endocrine pancreas
What procedures does a Medical Oncologist like Dr. Kunz typically perform?
As a Medical Oncologist, procedures performed by Dr. Pamela Kunz may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Kunz's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Kunz accept my insurance?
Dr. Kunz accepts most major insurance plans. Important: Please call our office at (203) 785-6879 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Kunz accept in New Haven, CT?
Dr. Kunz in New Haven, CT accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Cigna Group
CVS Health (formerly Aetna)
Elevance Health Inc. (formerly Anthem)
Humana
Medicare
Mutual of Omaha
State of Connecticut
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Kunz's office located?
Recognitions
Publications
Reassessment of the Current American Joint Committee on Cancer Staging System
, 2014
Seventh Edition (2010) of the AJCC
, 2013
Consensus Guidelines for the Magement and Treatment of Neuroendocrine Tumors
, 2013
Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis
, 2013
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
, 2012
Neoadjuvant Imatinib for Borderline Resectable GIST
, 2012
Capecitabine-Induced Chest Pain Relieved by Diltiazem
, 2012
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
, 2012
Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
, 2012
Neuroendocrine Tumors Clinical Practice Guidelines in Oncology
, 2012
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF
, 2011
Intensity-Modulated Radiation Therapy Versus Conventiol Radiation Therapy for Squamous Cell
, 2011
F-18-5-fluorouracil dymic positron emission tomography
, 2011
Comparison of Intensity-Modulated Radiotherapy
, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION
, 2010
Identification of a biomarker panel using a multiplex proximity ligation
, 2009
Escherichia coli O157 : H7 infection in nursing homes
, 2006
Cost-effectiveness of photodymic therapy for high-grade dysplasia in Barrett's esophagus
, 2004
Molecular alysis and pretal diagnosis of human fumarase deficiency
, 1998
Pancreatic neuroendocrine tumours
, 2014
Reassessment of the Current American Joint Committee on Cancer Staging System
, 2014
Seventh Edition (2010) of the AJCC
, 2013
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
, 2013
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET
, 2013
Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis
, 2013
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3
, 2012
Neoadjuvant Imatinib for Borderline Resectable GIST
, 2012
Capecitabine-Induced Chest Pain Relieved by Diltiazem
, 2012
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma
, 2012
Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
, 2012
Neuroendocrine Tumors Clinical Practice Guidelines in Oncology
, 2012
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
, 2012
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
, 2012
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF
, 2011
Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell
, 2011
Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement
, 2011
F-18-5-fluorouracil dynamic positron emission tomography
, 2011
Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate
, 2010
Comparison of Intensity-Modulated Radiotherapy
, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION
, 2010
Pathological response after chemoradiation for T3 rectal cancer
, 2010
Pathological response after chemoradiation for T3 rectal cancer.
, 2010
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
, 2010
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
, 2010
Identification of a biomarker panel using a multiplex proximity ligation
, 2009
Escherichia coli O157 : H7 infection in nursing homes
, 2006
Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
, 2004
Tandem mass spectrometry and newborn screening: Pilot data and review
, 2002
Molecular analysis and prenatal diagnosis of human fumarase deficiency
, 1998
What is Dr. Kunz's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Kunz's National Provider Identifier (NPI) number is 1225121932.
What common questions do patients ask about Dr. Kunz?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Kunz
What is Dr. Pamela Kunz's specialty?
Dr. Kunz is a Medical Oncologist near New Haven, CT.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Pamela Kunz affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Kunz is affiliated with Yale New Haven Hospital, York Street Campus which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Pamela Kunz accepting new patients in New Haven, CT?
Yes, Dr. Pamela Kunz is accepting new patients at this time.
Does Dr. Pamela Kunz offer online booking?
Please contact Dr. Kunz's office at (203) 785-6879 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Pamela Kunz?
Please contact Dr. Kunz's office at (203) 785-6879 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Pamela Kunz have?
Dr. Pamela Kunz is certified by the American Board of Internal Medicine and American Board of Radiology.
Other Medical Oncologist Near New Haven, CT
Internist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients